American Portfolios Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

American Portfolios Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.7K	Buy	+100	New	+$2.03K	﹤0.01%	3029

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

American Portfolios Advisors's RVNC Position: Q3 2022 in Review

American Portfolios Advisors opened a new position in Revance Therapeutics, Inc. (RVNC) in Q3 2022: 100 shares worth $2.7K. The stake represents ﹤0.01% of the portfolio and ranks #3029 among its holdings.

182 funds tracked by Wall St. Rank hold RVNC as of Q3 2022.

American Portfolios Advisors held 100 shares of Revance Therapeutics, Inc. worth $2.7K as of Q3 2022.
Revance Therapeutics, Inc. was a new American Portfolios Advisors position in Q3 2022.
Revance Therapeutics, Inc. made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #3029 holding.
182 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.